Xencor Inc — Investor Relations & Filings
Filings indexed
829
across all filing types
Latest filing
2026-05-06
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
XNCR
Xencor Inc. is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibody and cytokine therapeutics. The company's proprietary XmAb® protein engineering platform is used to create novel drug candidates with enhanced functionality, stability, and extended half-life for the treatment of cancer and autoimmune diseases. This technology enables the development of various therapeutic modalities, including bispecific antibodies designed to engage multiple targets simultaneously. Xencor is advancing a broad pipeline of candidates, with numerous programs in clinical testing, and its technology is utilized in several medicines marketed by partners.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Xencor Inc (0001326732) (Filer) | 2026-05-06 | English | |
| 8-K - Xencor Inc (0001326732) (Filer) | 2026-05-05 | English | |
| DEF 14A - Xencor Inc (0001326732) (Filer) | 2026-04-27 | English | |
| 8-K - Xencor Inc (0001326732) (Filer) | 2026-04-27 | English | |
| SCHEDULE 13G - Xencor Inc (0001326732) (Subject) | 2026-03-31 | English | |
| SCHEDULE 13G/A - Xencor Inc (0001326732) (Subject) | 2026-03-27 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 41996178 | 10-Q - Xencor Inc (0001326732) (Filer) | 2026-05-06 | English | ||
| 41376711 | 8-K - Xencor Inc (0001326732) (Filer) | 2026-05-05 | English | ||
| 37614926 | DEF 14A - Xencor Inc (0001326732) (Filer) | 2026-04-27 | English | ||
| 37610403 | 8-K - Xencor Inc (0001326732) (Filer) | 2026-04-27 | English | ||
| 33094516 | SCHEDULE 13G - Xencor Inc (0001326732) (Subject) | 2026-03-31 | English | ||
| 33064529 | SCHEDULE 13G/A - Xencor Inc (0001326732) (Subject) | 2026-03-27 | English | ||
| 32890164 | S-3ASR - XENCOR INC (0001326732) (Filer) | 2026-02-25 | English | ||
| 32890165 | 10-K - XENCOR INC (0001326732) (Filer) | 2026-02-25 | English | ||
| 32890163 | 8-K - XENCOR INC (0001326732) (Filer) | 2026-02-25 | English | ||
| 28901042 | 4 Filing | 2026-01-26 | English | ||
| 28901066 | 8-K Filing | 2026-01-08 | English | ||
|
2025
4 filings
| |||||
| 11849927 | FORM 4 | 2025-12-23 | English | ||
| 11849928 | FORM 4 | 2025-12-23 | English | ||
| 11849929 | Regulatory Filings 2025 | 2025-12-19 | English | ||
| 11849930 | Regulatory Filings 2025 | 2025-12-19 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Xencor Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32653/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32653 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32653 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32653 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32653}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Xencor Inc (id: 32653)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.